Review of Antifungal Resistance in West Africa
Open Access
- 30 May 2024
- journal article
- review article
- Published by Universitas Muhammadiyah Palangkaraya in Borneo Journal of Pharmacy
- Vol. 7 (2) , 187-197
Abstract
Knowledge of local and regional antimicrobial resistance (AMR) is important for clinical decision-making. However, surveillance capacity for fungal infections let alone antifungal resistance is lacking throughout West Africa, and current antifungal resistance data are sparse. We sought to address this gap by summarizing all available high-quality data on antifungal resistance in West Africa. We searched the PubMed database, African Journals Online archives, and free web searches in October and December 2023 using the terms "antifungal resistance" and "West Africa" to find articles published from 2010 onwards. Only 11 articles were included in our analysis most of which were cross-sectional and descriptive in design; relatively high levels of antifungal resistance (AFR) to commonly used antifungals were reported including (24-75%) resistance to fluconazole and ketoconazole, two of the most frequently-prescribed antifungals in this region. There is a high level of resistance to griseofulvin, ketoconazole, cotrimoxazole, and fluconazole among dermatophyte infections (80-100%) with 100% resistance to amphotericin B, ketoconazole, and fluconazole reported by the invasive fungal disease-causing pathogen Cryptococcus neoformans. Resistance to commonly used anti-fungal drugs is prevalent; raising concern that these drugs may no longer be useful for treating moderate or severe fungal infections in West Africa hence calling for countries to promote acceptance of antimicrobial stewardship as a programmatic strategy not just focused on bacterial resistance but also fungal resistance including pharmacy management, laboratory complete mycological investigations and dissemination of standard fungal susceptibility profiles.Keywords
This publication has 61 references indexed in Scilit:
- Fungal diseases in Africa: Closing the gaps in diagnosis and treatment through implementation research and advocacyJournal of Medical Mycology, 2023
- The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and RezafunginDrugs, 2021
- Tracing the Origin of Invasive Fungal InfectionsTrends in Microbiology, 2020
- The antifungal pipeline: a reality checkNature Reviews Drug Discovery, 2017
- Impact of antifungal prescription on relative distribution and susceptibility of Candida spp. – Trends over 10 yearsJournal of Infection, 2016
- Cryptococcus: from environmental saprophyte to global pathogenNature Reviews Microbiology, 2015
- Multi-drug resistant oral Candida species isolated from HIV-positive patients in South Africa and CameroonDiagnostic Microbiology and Infectious Disease, 2014
- Sensibilité in vitro des souches de Candida albicans d’origine vaginale aux antifongiques à Abidjan (Côte d’Ivoire)Journal of Medical Mycology, 2012
- Oral Candida isolates among HIV-infected subjects in NigeriaJournal of Microbiology, Immunology and Infection, 2011
- Comment on “Surviving sepsis campaign guidelines for the management of severe sepsis and septic shock” by Dellinger et al.Intensive Care Medicine, 2004